Peter C Enzinger MD

Oncology•Boston, MA

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to View Full Profile

44 Binney StDanafarber Cancer InstBoston, MA 02115
Phone+1 617-632-6855
Fax+1 617-632-5370

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of Rochester Medical CenterResidency, Internal Medicine, 1992 - 1995
The Warren Alpert Medical School of Brown UniversityClass of 1992

Certifications & Licensure

MA State Medical License 1999 - 2025
NY State Medical License 1995 - 2006
American Board of Internal Medicine Medical Oncology

Clinical Trials

Avastin and Taxotere for Esophagogastric Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 2
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 2
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies Start of enrollment: 2001 Nov 01
Completed
Phase 1
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer Start of enrollment: 2006 Sep 01
Completed
Phase 2
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 2
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
ACTIVE_NOT_RECRUITING
PHASE2
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Start of enrollment: 2013 Jan 01
Completed
Phase 2
Pembrolizumab in Refractory Advanced Esophageal Cancer Start of enrollment: 2017 Jan 18
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies.
Yelena Y Janjigian, Michael Cecchini, Kohei Shitara, Peter C Enzinger, Zev A Wainberg
JCO Precision Oncology. 2025-03-01
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Kimberly Perez, Matthew H Kulke, Hui Zheng, Jill Allen, Jeffrey Clark
The Oncologist. 2025-01-17
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
Ryan J Park, Milan Parikh, Leon Pappas, Moshe Sade-Feldman, Anupriya S Kulkarni
Medrxiv. 2024-10-08

Lectures

Pre/Post-Op Chemotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Merck, Roche and Bristol Myers Nab 4 of 6 Positive ODAC Votes for ‘Dangling’ Accelerated ApprovalsApril 29th, 2021
FDA Approves Pembrolizumab plus Platinum- & Fluoropyrimidine-Based Chemotherapy for Treatment of Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaMarch 23rd, 2021
FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaMarch 23rd, 2021
Join now to see all